News
Treatment of Low-Risk MDS According to NCCN Recommendations Version 1.2023
The latest recommendations from the American National Comprehensive Cancer Network (NCCN) for the diagnosis and treatment of myelodysplastic syndrome (MDS) include several updates incorporated into the graphical algorithms. Most patients with MDS have low-risk (LR) disease. We provide a summary of the current guidelines NCCN for the therapy of this group of patients, which differ depending on the presence of symptomatic anemia or clinically relevant thrombocytopenia or neutropenia.
ERS 2023: Erdostein and its Metabolite Met-1 Modulate Innate Immunity and Oxidative Stress in SARS-CoV-2 Infection
As part of the September congress of the European Respiratory Society (ERS 2023), the issue of…
Benefit of Empagliflozin in Patients with Chronic Kidney Disease – Results of the EMPA-KIDNEY Study
The sodium-glucose cotransporter 2 inhibitor (SGLT2i) empagliflozin is currently used to treat type…
Cardio-Renal-Metabolic Syndrome?
The association between type 2 diabetes (DM2) and atherosclerotic cardiovascular disease (ASCVD) is…
The Latest Updates of ESC Recommendations for Heart Failure Treatment
What is new in heart failure therapy? At the annual congress of the European Society of Cardiology…
Experience with Proton Radiotherapy for Anal Canal Carcinoma in Real Czech Practice
Radiotherapy has the potential to achieve complete tumor regression in patients with anal…
Facilitated Immunoglobulin Substitution Therapy in Paediatric Patients with Immunodeficiency – Real-World Data
Patients with humoral immunodeficiency are indicated for immunoglobulin substitution therapy. The…
Incidence of Osteoporosis in Patients with Atrial Fibrillation Treated with Different Oral Anticoagulants
Previous research has suggested an increased risk of osteoporosis and osteoporotic fractures in…
Results of Levothyroxine Treatment in Pregnant Women with Recurrent Pregnancy Losses with Subclinical Hypothyroidism or Anti-TPO Antibody Positivity
A recent meta-analysis of 15 studies involving a total of 1911 women with a history of recurrent…
Nirmatrelvir/ritonavir reduces the risk of hospitalization for COVID-19 even in the era of predominant omicron subvariants BA.4 and BA.5
One of the first studies to evaluate the efficacy of nirmatrelvir/ritonavir in non-hospitalized…
Conferences
News from the world of medicine
All conferences
Popular this week
- Multiple system atrophy
- Intermittent Fasting May Carry Significant Health Risks
- How Compassion Fatigue Threatens Doctors and Other Healthcare Workers
- Tuberous Sclerosis
- Modern approaches enhancing the efficiency of antibiotic therapy in hospital practice